JSM 2011 Online Program
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Activity Details
|
|||
652 * | Thu, 8/4/2011, 10:30 AM - 12:20 PM | CC-A205 | |
Decisionmaking in Drug Development Using Modeling and Simulation — Topic Contributed Papers | |||
Biopharmaceutical Section | |||
Organizer(s): Yi Liu, Millennium: The Takeda Oncology Company | |||
Chair(s): Mingxiu Hu, Millennium: The Takeda Oncology Company | |||
10:35 AM | Prediction of Phase III Survival Outcomes Using Phase II Surrogate Marker Results Through Modeling and Simulation — Yi Liu, Millennium: The Takeda Oncology Company ; Mingxiu Hu, Millennium: The Takeda Oncology Company ; Shan Yang, Iowa State University ; Guohui Liu, Millennium: The Takeda Oncology Company ; Hongliang Shi, Millennium: The Takeda Oncology Company | ||
10:55 AM | Enabling Phase III Go/No-Go Decision Using Phase I/II Study Data — Jiang Qian, Abbott Laboratories ; Ya-Hui Hsu, Abbott Laboratories | ||
11:15 AM | Assessment of Dosing Strategies for Anticancer Drugs via Nonlinear Mixed Model — Guohui Liu, Millennium: The Takeda Oncology Company ; Xuedong Chi, Millennium Pharmaceuticals | ||
11:35 AM | Two Examples on the Use of Simulations to Guide Model Selections in MMRM Analyses — Peiling Yang, U.S. Food and Drug Administration ; Phillip Dinh, U.S. Food and Drug Administration | ||
11:55 PM | Floor Discussion |
2011 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.